trial

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

NCTId NCT01003379
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 184 (actual)
Sponsored by Targacept Inc.
Primary completion 2010-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
184 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-10
Primary completion
2010-11
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
TC-5619

Sponsors

Targacept Inc.Lead Sponsor

Investigators

1
Jeffrey A. Lieberman, MDPrincipal Investigator

Sites

16 total
National City, United StatesTorrance, United StatesAtlanta, United StatesWichita, United StatesCedarhurst, United StatesNew York, United StatesAustin, United StatesGuntur, IndiaHyderabaad, IndiaHyderabaad, IndiaVisakhapatnam, IndiaVisakhapatnam, India

Linked catalysts

1
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cogniti — primary completion2010-11

Facts & assertions

4 sourced
Enrollment
184
Phase
PHASE2
Primary Completion Date
2010-11
Status
COMPLETED
relationships
The graph out of here
drug
TC-5619
drug
lead_sponsor
Targacept Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Jeffrey A. Lieberman, MD
person